- Home
- DQ vs MNKD Comparison
DQ vs MNKD Comparison
Compare DQ & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DQ | MNKD |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2010 | 2004 |
Fundamental Metrics
Financial Performance| Metric | DQ | MNKD |
|---|---|---|
| Price | $27.00 | $5.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $32.50 | $10.08 |
| AVG Volume (30 Days) | 806.9K | ★ 3.7M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | N/A | ★ 0.10 |
| Revenue | ★ $639,063,000.00 | $313,787,000.00 |
| Revenue This Year | N/A | $21.40 |
| Revenue Next Year | $60.25 | $25.03 |
| P/E Ratio | ★ N/A | $55.78 |
| Revenue Growth | N/A | ★ 17.43 |
| 52 Week Low | $12.41 | $3.38 |
| 52 Week High | $36.59 | $6.51 |
Technical Indicators
Market Signals| Indicator | DQ | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 48.65 |
| Support Level | $23.96 | $5.03 |
| Resistance Level | $28.76 | $6.05 |
| Average True Range (ATR) | 1.24 | 0.30 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 42.74 | 39.53 |
Price Performance
Historical ComparisonAbout DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.